This is a working overview of angiotensin IV, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-18 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
The three substrates of this enzyme are 3''-deamino-3''-oxonicotianamine, reduced nicotinamide adenine dinucleotide (NADH), and a proton. Its products are 2'-deoxymugineic acid and oxidised (NAD+). This enzyme can also use the alternative cofactor, nicotinamide adenine dinucleotide phosphate. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 2-deoxymugineic acid:NAD(P)+ 3-oxidoreductase. It is part of the pathway which converts the siderophore, nicotianamine, to other metal-chelating molecules in higher plants. These allow the plant to efficiently take up metals such as zinc and iron from the soil.
== Structure == SUMO proteins are small; most are around 100 amino acids in length and 12 kDa in mass. The exact length and mass varies between SUMO family members and depends on which organism the protein comes from. Although SUMO has very little sequence identity with ubiquitin (less than 20%) at the amino acid level, it has a nearly identical structural fold. SUMO protein has a unique N-terminal extension of 10-25 amino acids which other ubiquitin-like proteins do not have. This N-terminal is found related to the formation of SUMO chains. The structure of human SUMO1 is depicted on the right. It shows SUMO1 as a globular protein with both ends of the amino acid chain (shown in red and blue) sticking out of the protein's centre. The spherical core consists of an alpha helix and a beta sheet. The diagrams shown are based on an NMR analysis of the protein in solution.
=== Liquid chromatography EI-MS === Two recent approaches for coupling capillary scale liquid chromatography-electron ionization mass spectrometry (LC-EI-MS) can be incorporated for the analysis of various samples. These are capillary-scale EI-based LC/MS interface and direct-EI interface. In the capillary EI the nebulizer has been optimized for linearity and sensitivity. The direct-EI interface is a miniaturized interface for nano- and micro-HPLC in which the interfacing process takes place in a suitably modified ion source. Higher sensitivity, linearity, and reproducibility can be obtained because the elution from the column is completely transferred into the ion source. Using these two interfaces electron ionization can be successfully incorporated for the analysis of small and medium-sized molecules with various polarities. The most common applications for these interfaces in LC-MS are environmental applications such as gradient separations of the pesticides, carbaryl, propanil, and chlorpropham using a reversed phase, and pharmaceutical applications such as separation of four anti-inflammatory drugs, diphenyldramine, amitriptyline, naproxen, and ibuprofen. Another method to categorize the applications of electron ionization is based on the separation technique which is used in mass spectroscopy. According to this category most of the time applications can be found in time of flight (TOF) or orthogonal TOF mass spectrometry (OA-TOF MS), Fourier transform ion cyclotron resonance (FT-ICR MS) and quadrupole or ion trap mass spectrometry.
Sources: en.wikipedia.org
== Environmental risk factors == Exposures to pesticides, metals, solvents (trichloroethylene), other toxicants (carbon disulfide), and air pollution are known factors in the development of Parkinson's disease. The World Health Organization (WHO) recommends reducing exposure to environmental factors associated with PD, including pesticides, trichloroethylene (TCE), and air pollution. Pesticides, TCE and some air pollutants appear to trigger PD pathology through their effects on key mechanisms involved in mitochondrial dysfunction, oxidative stress, and neuroinflammation. The cumulative effects of many different environmental exposures over a lifetime (the exposome) interact with underlying genetic factors to influence the development and progression of neurodegenerative diseases. The brain is particularly vulnerable to compounds that are able to cross the blood-brain barrier. Body-first and brain-first models of Parkinson's disease indicate possible connections between known environmental risk factors and PD mechanisms. Toxicants such as pesticides, industrial chemicals, and air pollution are usually inhaled, ingested, or both. In the nasal cavity and gut, they engage directly with mucosal surfaces where inflammation can occur. Pathways which can carry inflammation and toxins from the olfactory system and gut to the brain are well established. Key mechanisms are increasingly understood.
As with other hallucinogens, these substances are often taken for the purposes of facilitating spiritual processes, mental reflection or recreation. Some research chemicals on the market were not psychoactive, but can be used as precursors in the synthesis of other potentially psychoactive substances, for example, 2C-H, which could be used to make 2C-B and 2C-I among others. Extensive surveys of structural variations have been conducted by pharmaceutical corporations, universities and independent researchers over the last century, from which some of the presently available research chemicals derive. One particularly notable researcher is Alexander Shulgin, who presented syntheses and pharmacological explorations of hundreds of substances in the books TiHKAL and PiHKAL (co-authored with Ann Shulgin), and served as an expert witness for the defense in several court cases against manufacturers of psychoactive drugs. The majority of chemical suppliers sold research chemicals in bulk form as powder, not as pills, as selling in pill form would invalidate the claims that they were being sold for non-consumptive research. Active dosages vary widely from substance to substance, ranging from micrograms to hundreds of milligrams, but while it is critical for the end user to weigh doses with a precision scale, instead of guessing ("eyeballing"), many users did not do this and this led to many emergency room visits and several deaths, which were a prominent factor leading to the emergency scheduling of several substances and eventually Operation Web Tryp.
Most of the sugar production in India takes place at mills owned by local cooperative societies. The members of the society include all farmers, small and large, supplying sugarcane to the mill. Over the last fifty years, the local sugar mills have played a crucial part in encouraging political participation and as a stepping stone for aspiring politicians. This is particularly true in the state of [[ Cooperative sugar factories in Maharashtra|Maharashtra]] where a large number of politicians belonging to the Congress party or NCP had ties to sugar cooperatives from their local area and has created a symbiotic relationship between the sugar factories and local politics. However, the policy of "profits for the company but losses to be borne by the government", has made a number of these operations inefficient.
=== Hydrothermal self-assembly === Graphene has been prepared by using a sugar like glucose, fructose, etc. This substrate-free "bottom-up" synthesis is safer, simpler and more environmentally friendly than exfoliation. The method can control the thickness, ranging from monolayer to multilayer, which is known as the "Tang-Lau Method".
Sources: en.wikipedia.org
== Atomic spectroscopy == Electrons exist in energy levels (i.e. atomic orbitals) within an atom. Atomic orbitals are quantized, meaning they exist as defined values instead of being continuous (see: atomic orbitals). Electrons may move between orbitals, but in doing so they must absorb or emit energy equal to the energy difference between their atom's specific quantized orbital energy levels. In optical spectroscopy, energy absorbed to move an electron to a higher energy level (higher orbital) and/or the energy emitted as the electron moves to a lower energy level is absorbed or emitted in the form of photons (light particles). Because each element has a unique number of electrons, an atom will absorb/release energy in a pattern unique to its elemental identity (e.g. Ca, Na, etc.) and thus will absorb/emit photons in a correspondingly unique pattern. The type of atoms present in a sample, or the amount of atoms present in a sample can be deduced from measuring these changes in light wavelength and light intensity. Atomic spectroscopy is further divided into atomic absorption spectroscopy and atomic emission spectroscopy. In atomic absorption spectroscopy, light of a predetermined wavelength is passed through a collection of atoms. If the wavelength of the source light has energy corresponding to the energy difference between two energy levels in the atoms, a portion of the light will be absorbed. The difference between the intensity of the light emitted from the source (e.g., lamp) and the light collected by the detector yields an absorbance value.
== History == The brewery started as a small, casual pub in the alleyways of Gyeongnidan in Seoul. The idea to start the pub was inspired by Tudor's article in The Economist, which claimed: "brewing remains just about the only useful activity at which North Korea beats the South." The pub began selling Bill's Pale Ale, The Booth's first brew, along with a small selection of pizza. After realizing how crucial the cold chain transportation system was to maintaining the quality and flavor of beer, the owners established the first cold chain import and distribution system, The Booth Cold Chain. This was soon importing beers from Mikkeller, Evil Twin, To Øl, and 8 Wired. Two crowdfunding campaigns titled Equity for Booth were launched, in September 2015 and February 2017.
== Preparation == Tofu has little flavor or smell of its own. Consequently, tofu can be used in both savory and sweet dishes, acting as a bland background for presenting the flavors of the other ingredients used. In order to flavor the tofu, it is often marinated in soy sauce, chillis, or sesame oil. A common cooking technique in many parts of East and Southeast Asia involves deep frying tofu in vegetable oil like sunflower or canola.
Insulin therapy can be injection under the skin multiple times a day, or can be delivered continuously as a basal amount with boluses for high blood sugar or before meals using an insulin pump. A diabetic diet, exercise, and lifestyle modifications are considered cornerstones of management. If left untreated, type 1 diabetes results in death. Type 1 diabetes can cause many complications if blood sugar control is not very well controlled. Complications of relatively rapid onset include diabetic ketoacidosis and nonketotic hyperosmolar coma. Long-term complications include heart disease, stroke, kidney failure (Diabetic Nephropathy), foot ulcers, and damage to the eyes (diabetic retinopathy). As insulin lowers blood sugar levels, complications may arise from low blood sugar if more insulin is taken than necessary. Type 1 diabetes makes up an estimated 5–10% of all diabetes cases. The number of people affected globally is unknown, although it is estimated that about 80,000 children develop the disease each year. Within the United States the number of people affected is estimated to be one to three million. Rates of disease vary widely, with approximately one new case per 100,000 per year in East Asia and Latin America and around 30 new cases per 100,000 per year in Scandinavia and Kuwait. It typically begins in children and young adults but can begin at any age.
=== Solvent extraction === In the solvent extraction a mixture of an extractant in a solvent (sometimes called a diluent) is used to extract a metal ions from one phase to another. In solvent extraction this mixture is often referred to as the "organic" because the main constituent (diluent) is some type of hydrocarbon derivative. Di(2-ethylhexyl)phosphoric acid (the extractant) and tributyl phosphate (the diluent) are used for the liquid–liquid extraction from aqueous solutions. The combination of di(2-ethylhexyl)phosphoric acid and tributyl phosphate are also used in nuclear reprocessing.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.